Brit Mollenhauer, MD, University Medical Center Göttingen, Göttingen, Germany, discusses successes in Parkinson’s disease diagnostic research. One area of success was the development of seeding assays. They can improve clinical diagnosis in early disease patients, but still require validation. Neurofilament light chains also show promise as the first blood biomarker. Dr Mollenhauer also discusses the promise of The Parkinson Progression Marker Initiative 2.0 clinical trial (NCT04477785). This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).